PST 2744

Known as: PST-2744, PST2744 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2011
0120022011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Pro-arrhythmic risk strongly limits the therapeutic value of current inotropic interventions. Istaroxime (previously PST2744) is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
PST2744 [Istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] is a novel inotropic agent that… (More)
  • table 1
  • table 2
  • figure 1
  • figure 3
  • figure 5
Is this relevant?
2007
2007
Istaroxime (PST2744) is a luso-inotrope that stimulates the sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a… (More)
Is this relevant?
2005
2005
OBJECTIVE To gain some insight on the lesser arrhythmogenic properties of PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Inotropic agents for acute decompensated heart failure are associated with a lack of efficacy or increased mortality. New… (More)
Is this relevant?
2003
2003
(E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) is a novel Na(+)/K(+) pump inhibitor with positive… (More)
Is this relevant?
2002
2002
The novel Na(+)/K(+)-ATPase inhibitor (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) was… (More)
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • table 1
Is this relevant?